First step toward duchenne treatment: drug safety check in healthy volunteers
NCT ID NCT07347548
First seen Jan 17, 2026 · Last updated May 08, 2026 · Updated 11 times
Summary
This early-stage trial tests the safety and how the body handles a new drug called GRT6019 in 24 healthy men. The drug is being developed for Duchenne muscular dystrophy, but this study only checks for side effects and drug levels in the blood. Participants take the drug for 4 weeks and are followed for 5 more weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotrial Clinical Pharmacology Unit
Rennes, 35042, France
Conditions
Explore the condition pages connected to this study.